As of June 10, 2025, Xenetic Biosciences Inc (XBIO) reports a ROA (Return on Assets) of -57.38%.
ROA (Return on Assets) evaluates how effectively a company turns its assets into profits, showcasing resource utilization.
Historical Trend of Xenetic Biosciences Inc's ROA (Return on Assets)
Over recent years, Xenetic Biosciences Inc's ROA (Return on Assets) has shown a stable trend. The table below summarizes the historical values:
| Date | ROA (Return on Assets) |
|---|---|
| 2024-12-31 | -57.38% |
| 2023-12-31 | -38.99% |
| 2022-12-31 | -44.50% |
| 2021-12-31 | -28.51% |
| 2020-12-31 | -82.63% |
This slight downward trend highlights how Xenetic Biosciences Inc manages its efficiency in using assets to generate earnings over time.
Comparing Xenetic Biosciences Inc's ROA (Return on Assets) to Peers
To better understand Xenetic Biosciences Inc's position, it's useful to compare its ROA (Return on Assets) against industry peers. Below are selected comparisons:
| Company | ROA (Return on Assets) |
|---|---|
| Xenetic Biosciences Inc (XBIO) | -57.38% |
| Kane Biotech Inc (KNE.V) | 244.49% |
| Advanced Proteome Therapeutics Corporation (APC.V) | 119.36% |
| Regeneron Pharmaceuticals Inc (REGN) | 11.69% |
| Amgen Inc (AMGN) | 4.45% |
| Abbvie Inc (ABBV) | 3.17% |
Compared to its competitors, Xenetic Biosciences Inc's ROA (Return on Assets) is about average compared to peers, indicating typical asset efficiency for the industry.